The Prognostic Impact of Absolute Lymphocyte and Monocyte Counts at Diagnosis of Diffuse Large B-Cell Lymphoma in the Rituximab Era

Kazunari Aoki    Sumie Tabata    Noboru Yonetani    Akiko Matsushita
Takayuki Ishikawa
Department of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Kobe, Japan

Introduction

The International Prognostic Index (IPI), established in 1993 to aid prognosis prediction in patients with diffuse large B-cell lymphoma (DLBCL) receiving treatment with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) or other CHOP-like regimens, remains valid in the rituximab era; however, the 3-year overall survival (OS) rate for patients with a high-risk IPI (H-IPI) is around 60% [1]. Therefore, a new risk stratification system, which can identify patients with the dismal prognosis, is required.

Recently, gene expression profiling studies in non-Hodgkin lymphomas showed that the genes expressed by tumor-infiltrating lymphocytes and myeloid-derived cells predict clinical outcomes and indicate that factors related to the host’s adaptive immunity and the tumor microenvironment are significant prognostic variables in non-Hodgkin lymphomas [2, 3]. Furthermore, Wilcox et al. [4] reported that in patients with DLBCL, the combination of the absolute lymphocyte count (ALC) and the absolute monocyte count (AMC) at diagnosis gave a prognostic score that was independent of the IPI; however, this model requires validation in other patient cohorts. Therefore, we retrospectively evaluated the prognostic impact of the ALC and AMC at diagnosis in patients with DLBCL in the rituximab era.

Key Words
Diffuse large B-cell lymphoma · Lymphocyte · Monocyte · Rituximab

Abstract

Background: A recent report showed that the combination of the absolute lymphocyte count (ALC) and the absolute monocyte count (AMC) at diagnosis gave a prognostic score in diffuse large B-cell lymphoma (DLBCL). However, this model requires validation in other patient cohorts. Methods: We retrospectively evaluated the prognostic impact of the combination of the ALC and the AMC at diagnosis in a cohort of 299 DLBCL patients who were treated in the rituximab era at a single institution. Results: In univariate analyses, an ALC ≤ 1.0 × 10^9/l [4-year overall survival (OS) rate 47.0 vs. 79.4%; p < 0.001] and an AMC ≥ 0.63 × 10^9/l (4-year OS rate 52.4 vs. 75.6%; p < 0.001) were associated with inferior OS, respectively. In multivariate analyses, an ALC ≤ 1.0 × 10^9/l and an AMC ≥ 0.63 × 10^9/l were significantly associated with inferior OS independently of the International Prognostic Index. Furthermore, the combination of ALC and AMC could identify patients with the dismal prognosis; the 4-year OS rates for patients with ALC ≤ 1.0 × 10^9/l and AMC ≥ 0.63 × 10^9/l were 18.8%. Conclusions: The combination of ALC and AMC at diagnosis may be useful for the prognostic stratification of patients with DLBCL.
Patients and Methods

Data from consecutive patients diagnosed with DLBCL at our hospital between 1 January 2004 and 31 January 2011, all of whom were treated with CHOP plus rituximab (R-CHOP therapy) with curative intent, were retrospectively evaluated. Patients with intravascular large B-cell lymphoma, primary effusion lymphoma or mediastinal B-cell lymphoma and patients with central nervous system involvement at diagnosis, patients with a history of indolent lymphoma and HIV-positive patients were excluded. This study was approved by the institutional review board of the Ethics Committee and complied with the Helsinki Declaration.

The primary outcome measure was OS. OS was defined as the time (in months) from the date of diagnosis to the date of death from any cause. The objective of the study was to determine the prognostic impact of the ALC and the AMC at diagnosis. ALC and AMC were obtained from a standard complete blood count and a differential was performed manually at the time of diagnosis. We used an ALC cutoff of 1.0 × 10^9/l and an AMC cutoff of 0.63 × 10^9/l because these cutoffs were used in the previous report [4]. The characteristics of the 229 patients are listed in table 1. One hundred and sixteen patients (50.7%) had Ann Arbor stage III or IV disease, and 71 (31.0%) had a performance status of ≥2. Serum lactate dehydrogenase levels were higher than normal in 122 patients (53.3%). The IPI was calculated as low risk (L-IPI) in 77 patients (33.6%), low-intermediate risk (LI-IPI) in 57 patients (24.9%), high-intermediate risk (HI-IPI) in 38 patients (16.6%) and H-IPI in 57 patients (24.9%), which was significantly higher than that in the patient cohort of the previous report [L-IPI in 104 patients (45.6%), LI-IPI in 68 patients (26.6%), HI-IPI in 59 patients (23.0%), and H-IPI in 25 patients (9.8%); p = 0.006] [4]. The median ALC and AMC were 1.3 × 10^9/l (range 0.16–3.8) and 0.39 × 10^9/l (range 0–2.4), respectively. Whereas the ALC in this patient cohort was similar to that in the patient cohort in the previous report (median 1.2 × 10^9/l, range 0.87–1.8), the AMC in this patient cohort was lower than that in the patient cohort of the previous report (median 0.63 × 10^9/l, range 0.47–0.83) [4]. The unadjusted 4-year OS rates for the L-IPI, LI-IPI, HI-IPI and H-IPI patients were 86.5% (n = 77), 74.0% (n = 57), 65.1% (n = 38) and 48.3% (n = 57), respectively (p < 0.001; fig. 1a).

The unadjusted 4-year OS rates for patients with an ALC ≤1.0 × 10^9/l (n = 65) and patients with an ALC >1.0 × 10^9/l (n = 164) were 47.0% (95% CI 32.4–60.3) and 79.4% (95% CI 71.5–85.4), respectively (p < 0.001; fig. 1b). The unadjusted 4-year OS rates for patients with an AMC ≥0.63 × 10^9/l (n = 48) and patients with an AMC <0.63 × 10^9/l (n = 181) were 52.4% (95% CI 36.5–66.2) and 75.6% (95% CI 67.6–81.9), respectively (p < 0.001; fig. 1c). In multivariate analyses, an ALC ≤1.0 × 10^9/l (HR 3.4, 95% CI 2.1–5.6; p < 0.001) and an AMC ≥0.63 × 10^9/l (HR 2.6, 95% CI 1.5–4.3; p < 0.001) were independently associated with inferior OS (table 2). Therefore, we combined these dichotomized variables to generate an ‘immunological index’ (IMI) and stratified patients into three risk groups: low (ALC >1.0 × 10^9/l and AMC <0.63 × 10^9/l), intermediate (ALC ≤1.0 × 10^9/l or AMC ≥0.63 × 10^9/l) and high (ALC ≤1.0 × 10^9/l and AMC ≥0.63 × 10^9/l). The unadjusted 4-year OS rates for patients with low- (L-IMI; n = 128), intermediate- (I-IMI; n = 89) and high-risk IMI (H-IMI; n = 12) were 83.8% (95% CI 74.8–89.8), 59.3% (95% CI 47.1–69.5) and 18.8% (95% CI 3.0–45.1), respectively (p < 0.001; fig. 2a).

We next investigated whether IMI was associated with inferior OS independently of the IPI. Among the L-IPI and LI-IPI patients, the unadjusted 4-year OS rates for L-IMI (n = 100), I-IMI (n = 33) and H-IMI (n = 1) patients were 87.0% (95% CI 77.4–92.7), 62.5% (95% CI 39.7–78.7) and 100%, respectively (p = 0.014; fig. 2b). Among the HI-IPI and H-IMI patients, the unadjusted 4-year OS rates for L-IMI (n = 28), I-IMI (n = 56) and H-IMI (n = 11) patients were 71.0% (95% CI 44.0–86.7), 56.0% (95% CI 41.1–68.5) and 10.4% (95% CI 0.6–36.8), respectively (p = 0.001; fig. 2c). Furthermore, multivariate analyses showed that HI-IPI or H-IMI (HR 1.9, 95% CI 1.0–3.3; p = 0.03), an ALC ≤1.0 × 10^9/l (HR 2.8, 95% CI 1.6–4.7; p < 0.001) and an AMC ≥0.63 × 10^9/l (HR 2.2, 95% CI 1.3–3.7; p = 0.005) were independently associated with inferior OS (table 2).
The present study showed that in DLBCL patients receiving R-CHOP therapy, ALC and AMC were associated with inferior OS independently of the IPI, confirming data from a previous report [4]. The finding that AMC and ALC act as prognostic indicators can be explained by the following mechanisms: myeloid-derived cells, including monocytes and their progeny, contribute to the suppression of host antitumor immunity and play an important role in tumor angiogenesis, which in turn promotes tumorigenesis [5–7]; on the other hand, lymphopenia is a surrogate marker of host immunological incompetence [8]. In addition, lymphocytes (including natural killer cells) are important mediators of antibody-dependent cell-mediated cytotoxicity and may be required for rituximab-mediated destruction of malignant B cells [9].

Given that in the rituximab era, the IPI cannot identify a population with an OS rate of <50%, the IMI could be a useful additional tool for predicting the prognosis of DLBCL patients; the 4-year OS rate for the H-IMI patients was <20%. Furthermore, compared with other more complicated and expensive methods such as gene expression profiling or interim positron emission tomography scans [10–12], the IMI is a very simple and low-cost tool for predicting the outcome of DLBCL patients. However, its efficacy was limited in the current study; only 5.1% (12/229) of patients were identified as H-IMI, whereas Wilcox et al. [4] (using the same model) identified 15.6% (40/256) of patients as H-IMI. This discrepancy might be ascribed to the difference in the value of AMC at diagnosis between the two patient cohorts. While an ALC cutoff of 1.0 × 10⁹/l was used in previous studies,
the optimal cutoff point for the AMC has not been determined [13, 14]. It is plausible that reducing the AMC cutoff point would identify a larger proportion of patients with a dismal prognosis. Indeed, if we reduced the AMC cutoff point to 0.50 × 10^9/l, the unadjusted 4-year OS rates for patients with L-IMI (n = 105, 45.9%), I-IMI (n = 101, 44.1%) and H-IMI (n = 23, 10.0%) were 86.4% (95% CI 76.4–92.4), 62.9% (95% CI 51.7–72.1) and 32.6% (95% CI 12.3–54.9), respectively (p < 0.001).

The results of this study should be interpreted cautiously, as it had several limitations; it was a retrospective study of a relatively small sample size, with a relatively short median follow-up period. Thus, these results should be validated in larger, prospective studies with a longer follow-up.

In conclusion, ALC and AMC at diagnosis may be useful for the prognostic stratification of patients with DLBCL in the rituximab era, particularly as they have the potential to identify patients at high risk of short survival. To improve the clinical outcome for high-risk patients identified by the ALC and the AMC, further investigation of new therapeutic strategies, targeting tumor-infiltrating lymphocytes and myeloid-derived cells, are warranted.

**Acknowledgements**

We are indebted to all the physicians at the Kobe City Medical Center General Hospital. This work was supported by the Kasahara Memorial Foundation for Medical Research.

**Disclosure Statement**

The authors declare no conflict of interest.
References


